Cargando…
The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness
BACKGROUND: Gulf War (GW) Illness (GWI) is a debilitating condition with a complex constellation of immune, endocrine and neurological symptoms, including cognitive impairment, anxiety and depression. We studied a novel model of GWI based on 3 known common GW exposures (GWE): (i) intranasal lipopoly...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665704/ https://www.ncbi.nlm.nih.gov/pubmed/33186383 http://dx.doi.org/10.1371/journal.pone.0242427 |
_version_ | 1783610023294795776 |
---|---|
author | Keledjian, Kaspar Tsymbalyuk, Orest Semick, Stephen Moyer, Mitchell Negoita, Serban Kim, Kevin Ivanova, Svetlana Gerzanich, Volodymyr Simard, J. Marc |
author_facet | Keledjian, Kaspar Tsymbalyuk, Orest Semick, Stephen Moyer, Mitchell Negoita, Serban Kim, Kevin Ivanova, Svetlana Gerzanich, Volodymyr Simard, J. Marc |
author_sort | Keledjian, Kaspar |
collection | PubMed |
description | BACKGROUND: Gulf War (GW) Illness (GWI) is a debilitating condition with a complex constellation of immune, endocrine and neurological symptoms, including cognitive impairment, anxiety and depression. We studied a novel model of GWI based on 3 known common GW exposures (GWE): (i) intranasal lipopolysaccharide, to which personnel were exposed during desert sand storms; (ii) pyridostigmine bromide, used as prophylaxis against chemical warfare; and (iii) chronic unpredictable stress, an inescapable element of war. We used this model to evaluate prophylactic treatment with the PPARγ agonist, rosiglitazone (ROSI). METHODS: Rats were subjected to the three GWE for 33 days. In series 1 and 2, male and female GWE-rats were compared to naïve rats. In series 3, male rats with GWE were randomly assigned to prophylactic treatment with ROSI (GWE-ROSI) or vehicle. After the 33-day exposures, three neurofunctional domains were evaluated: cognition (novel object recognition), anxiety-like behaviors (elevated plus maze, open field) and depression-like behaviors (coat state, sucrose preference, splash test, tail suspension and forced swim). Brains were analyzed for astrocytic and microglial activation and neuroinflammation (GFAP, Iba1, tumor necrosis factor and translocator protein). Neurofunctional data from rats with similar exposures were pooled into 3 groups: naïve, GWE and GWE-ROSI. RESULTS: Compared to naïve rats, GWE-rats showed significant abnormalities in the three neurofunctional domains, along with significant neuroinflammation in amygdala and hippocampus. There were no differences between males and females with GWE. GWE-ROSI rats showed significant attenuation of neuroinflammation and of some of the neurofunctional abnormalities. CONCLUSION: This novel GWI model recapitulates critical neurofunctional abnormalities reported by Veterans with GWI. Concurrent prophylactic treatment with ROSI was beneficial in this model. |
format | Online Article Text |
id | pubmed-7665704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-76657042020-11-18 The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness Keledjian, Kaspar Tsymbalyuk, Orest Semick, Stephen Moyer, Mitchell Negoita, Serban Kim, Kevin Ivanova, Svetlana Gerzanich, Volodymyr Simard, J. Marc PLoS One Research Article BACKGROUND: Gulf War (GW) Illness (GWI) is a debilitating condition with a complex constellation of immune, endocrine and neurological symptoms, including cognitive impairment, anxiety and depression. We studied a novel model of GWI based on 3 known common GW exposures (GWE): (i) intranasal lipopolysaccharide, to which personnel were exposed during desert sand storms; (ii) pyridostigmine bromide, used as prophylaxis against chemical warfare; and (iii) chronic unpredictable stress, an inescapable element of war. We used this model to evaluate prophylactic treatment with the PPARγ agonist, rosiglitazone (ROSI). METHODS: Rats were subjected to the three GWE for 33 days. In series 1 and 2, male and female GWE-rats were compared to naïve rats. In series 3, male rats with GWE were randomly assigned to prophylactic treatment with ROSI (GWE-ROSI) or vehicle. After the 33-day exposures, three neurofunctional domains were evaluated: cognition (novel object recognition), anxiety-like behaviors (elevated plus maze, open field) and depression-like behaviors (coat state, sucrose preference, splash test, tail suspension and forced swim). Brains were analyzed for astrocytic and microglial activation and neuroinflammation (GFAP, Iba1, tumor necrosis factor and translocator protein). Neurofunctional data from rats with similar exposures were pooled into 3 groups: naïve, GWE and GWE-ROSI. RESULTS: Compared to naïve rats, GWE-rats showed significant abnormalities in the three neurofunctional domains, along with significant neuroinflammation in amygdala and hippocampus. There were no differences between males and females with GWE. GWE-ROSI rats showed significant attenuation of neuroinflammation and of some of the neurofunctional abnormalities. CONCLUSION: This novel GWI model recapitulates critical neurofunctional abnormalities reported by Veterans with GWI. Concurrent prophylactic treatment with ROSI was beneficial in this model. Public Library of Science 2020-11-13 /pmc/articles/PMC7665704/ /pubmed/33186383 http://dx.doi.org/10.1371/journal.pone.0242427 Text en © 2020 Keledjian et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Keledjian, Kaspar Tsymbalyuk, Orest Semick, Stephen Moyer, Mitchell Negoita, Serban Kim, Kevin Ivanova, Svetlana Gerzanich, Volodymyr Simard, J. Marc The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness |
title | The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness |
title_full | The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness |
title_fullStr | The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness |
title_full_unstemmed | The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness |
title_short | The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness |
title_sort | peroxisome proliferator-activated receptor gamma (pparγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of gulf war illness |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665704/ https://www.ncbi.nlm.nih.gov/pubmed/33186383 http://dx.doi.org/10.1371/journal.pone.0242427 |
work_keys_str_mv | AT keledjiankaspar theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT tsymbalyukorest theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT semickstephen theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT moyermitchell theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT negoitaserban theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT kimkevin theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT ivanovasvetlana theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT gerzanichvolodymyr theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT simardjmarc theperoxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT keledjiankaspar peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT tsymbalyukorest peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT semickstephen peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT moyermitchell peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT negoitaserban peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT kimkevin peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT ivanovasvetlana peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT gerzanichvolodymyr peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness AT simardjmarc peroxisomeproliferatoractivatedreceptorgammappargagonistrosiglitazoneamelioratesneurofunctionalandneuroinflammatoryabnormalitiesinaratmodelofgulfwarillness |